

Amendments to the claims:

This listing of claims replaces all prior versions, and listings, of claims in the application.

Listing of claims:

Claims 1-11 (canceled).

12 (new): A blood plasma for human use prepared by the process comprising mixing, in the absence of blood or blood plasma from a blood-group O donor pool, from both pooled blood or blood plasma from donors that belong to Caucasian population and pooled blood or blood plasma from donors that belong to a non-Caucasian population,

- a) five to six parts of blood or blood plasma from donors having blood group A,
- b) four to five parts of blood or blood plasma from donors having blood group B, and
- c) zero to one part of blood or blood plasma from donors having blood group AB,

wherein 10% or more of the blood plasma is from donors that belong to the non-Caucasian population.

13 (new): The blood plasma according to claim 12 wherein the blood plasma is virus-inactivated.

- 14 (new): The blood plasma according to claim 12 wherein the blood plasma is virus-inactivated by solvent/detergent treatment, irradiation, pasteurisation, or nanofiltration or a combination thereof.
- 15 (new): The blood plasma according to claim 12 wherein the blood plasma is virus-inactivated by treatment with a detergent and tri-N-butylphosphate (TNBP).
- 16 (new): The blood plasma according to claim 12 wherein the blood plasma is virus-inactivated by treatment with a detergent and tri-N-butylphosphate (TNBP), wherein the detergent is an oxyethylated polyphenol or polyoxyethylene derivative of a fatty acid or a combination thereof.
- 17 (new): The blood plasma according to claim 12 wherein the blood plasma is virus-inactivated by treatment with a detergent and tri-N-butylphosphate (TNBP), wherein the detergent is an oxyethylated polyphenol or polyoxyethylene derivative of a fatty acid or a combination thereof, wherein the fatty acid is a medium- to long-chain fatty acid or the respective salt or a combination thereof.
- 18 (new): The blood plasma according to claim 12 wherein the blood plasma is virus-inactivated by treatment with a detergent and tri-N-butylphosphate (TNBP), wherein the detergent is an

oxyethylated polyphenol or polyoxyethylene derivative of a fatty acid or a combination thereof, wherein the fatty acid is caprylic acid or its respective salt or a combination thereof.

19 (new): The blood plasma according to claim 12 wherein the blood plasma is substantially free of virus inactivating agents.

20 (new): The blood plasma of claim 12 wherein the blood plasma has an ABO blood group specific antibody titre lower than 16 for anti-A and anti-B IgM antibodies, and lower than 64 for anti-A and anti-B IgG antibodies.

21 (new): The blood plasma of claim 12 wherein the blood plasma is in liquid, frozen, dried, or lyophilized form.

22 (new): A pharmaceutical composition comprising the blood plasma of claim 12 in the form of a transfusion unit dose.

23 (new): Use of the blood plasma of claim 12 for the treatment of a coagulation factor deficiency or thrombotic purpura comprising repeated large volume plasma exchange.

24 (new):A packaged unit of blood plasma for human use, wherein the blood plasma is the blood plasma of claim 12.